Uveal melanoma arises from stromal melanocytes and is the most prevalent primary intraocular tumor in adults. It poses a significant diagnostic and therapeutic challenge due to its high malignancy and early onset of metastases. In recent years, there has been a growing interest in the role of diverse immune cells in tumor cell development and metastasis. Using The Cancer Genome Atlas and the gene expression omnibus databases, and the CIBERSORT method, we investigated the topography of intra-tumor immune infiltration in uveal melanoma in this research. We evaluated the prognosis of uveal melanoma patients using the M2 macrophage immune cell infiltration score in conjunction with clinical tumor patient data. We built a prognostic model based on the distinctive genes of M2 macrophages and combined it with patients' clinical data in the database; we ran a survival prognostic analysis to authenticate the model's accuracy. The functional study revealed the importance of macrophage-associated genes in the development of uveal melanoma. Moreover, the reliability of our prediction model was verified by combining tumor mutational load, immune checkpoint, and drug sensitivity, respectively. Our study provides a reference for the follow-up study of uveal melanoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334534 | PMC |
http://dx.doi.org/10.1186/s12859-023-05396-9 | DOI Listing |
Am J Ophthalmol
December 2024
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia PA. Electronic address:
Purpose: Uveal melanoma (UM) represents the most prevalent and aggressive intraocular malignancy in adults. This study examined the outcomes of patients diagnosed with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel LINAC-based frameless technique.
Design: Retrospective, interventional case series.
Front Immunol
December 2024
Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Melanoma of the uveal tract or uveal melanoma (UM) originates from melanocytes of the eye and is the most common intraocular malignancy in adults. Despite considerable advances in diagnostic procedures and treatments, prognosis remains poor in those with advanced disease. Accordingly, although current treatments have an excellent local disease control rate, approximately 50% of patients develop metastatic relapse within 10 years.
View Article and Find Full Text PDFAppl Radiat Isot
December 2024
Department of Physics, Faculty of Science, University of Guilan, Rasht, Iran. Electronic address:
Uveal melanoma is the most common primary eye cancer with the highest incidence. BEBIG Ru/Rh ophthalmic plaques more used for the treatment of these eye malignancies, mainly malignancies with small to medium sizes. In this study, we evaluate dose distributions around a voxelized eye phantom due to CCA and CCB eye plaque using GATE code.
View Article and Find Full Text PDFHarefuah
December 2024
Ophthalmology Department, Shaare Tzedek Medical Center.
Malignant tumors of the eye are uncommon, yet of great importance due to their effect on the patient's life and vision. The most common primary intraocular tumors are retinoblastoma in children and uveal melanoma in adults. The most common periocular tumor is basal cell carcinoma in eyelids.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Uveal melanoma (UVM) is an aggressive tumor known for its high metastatic rate, making it necessary to delineate potential molecules that may promote the development of UVM. PLEK2 has been found to promote the progression and metastasis of some tumors, but its role in UVM has not yet been reported. Through this study, we hope to explore the effect of PLEK2 on the prognosis of UVM patients and to discover the potential functional role and intrinsic mechanism of PLEK2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!